The PKD Cures Act directs the National Institutes of Health to significantly expand research efforts focused on polycystic kidney disease, a genetic condition affecting approximately 500,000 Americans that commonly leads to kidney failure requiring dialysis or transplantation. The legislation requires the NIH to intensify basic, translational, and clinical research into PKD while promoting collaboration among federal agencies, academic institutions, and private sector partners, and to support training programs for researchers and clinicians specializing in the disease. The bill also mandates that the NIH establish a working group to develop a comprehensive research roadmap that identifies gaps, recommends public-private collaboration strategies, sets benchmarks for innovation milestones, and incorporates emerging technologies like artificial intelligence into PKD research and care. The working group must submit its report with findings and recommendations to Congress within 24 months of the bill's enactment. This legislation addresses the significant burden PKD places on Medicare, which currently spends approximately $3 billion annually treating end-stage renal disease caused by cystic kidney diseases like PKD.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.